MarketLens

Log in

What's Behind the Recent Insider Selling at NewAmsterdam Pharma (NAMS)

2 hours ago
SHARE THIS ON:

What's Behind the Recent Insider Selling at NewAmsterdam Pharma (NAMS)

Exclusive Content for Pro Members

Pro members only. Upgrade to access this article, premium analysis, and stock recommendations.

SHARE THIS ON:

Related Articles

Category

You may also like

Stock News3 days ago

Why Are Amphenol, Royal Caribbean, and Freeport Insiders Selling?

Insiders at Amphenol (APH), Royal Caribbean (RCL), and Freeport-McMoRan (FCX) have recently sold shares despite the companies holding strong industry positions and showing impressive past stock perfor...
Stock News3 days ago

Investors Heavily Search Novo Nordisk A/S (NVO): Here is What You Need to Know

Novo Nordisk (NVO) stock is currently seeing heavy user attention on Zacks.com. Investors are exploring the future outlook for the pharmaceutical company.
Stock News5 days ago

Is Novanta Stock a Buy or Sell After Its CEO Dumped 6,500 Shares?

Novanta CEO Matthijs Glastra sold 6,500 shares for ~$878K on Feb. 2, 2026, which represented 5.17% of his total holdings at that time.
Stock News6 days ago

Why Are C3is Shares Tumbling On Friday?

C3is (CISS) shares are declining Friday following an unspecified event that triggered the stock's drop today.

Breaking News

View All →

Top Headlines

View More →
Stock News2 hours ago

Nvidia has MORE demand than supply: Landsberg Bennett Private Wealth Management CIO

Stock News3 hours ago

Wall Street's Secret Weapon: This Artificial Intelligence (AI) Stock for 2026

Stock News3 hours ago

An Indian company is set to build a $2 billion AI hub with Nvidia's GPUs and go public. Here's what we know so far

Stock News4 hours ago

South Korea approves Google bid to export high-precision map data

Stock News6 hours ago

Nvidia Just Crushed Earnings. 1 No-Brainer ETF To Buy Now